help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kemp, J. P.
Right arrow Articles by Van As, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kemp, J. P.
Right arrow Articles by Van As, A.

Am. J. Respir. Crit. Care Med., Vol 150, No. 6, Dec 1994, 1612-1615.

Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm

JP Kemp, RJ Dockhorn, WW Busse, ER Bleecker and A Van As
Allergy and Asthma Medical Group and Research Center, San Diego, California 92123.

Physical exercise is a common trigger for bronchial asthma. We evaluated the preventive effect on exercise-induced bronchospasm (EIB) of a single 42 micrograms dose of salmeterol, a uniquely long-acting inhaled bronchodilator, and compared salmeterol with 180 micrograms albuterol in two independent, randomized, double-blind, placebo- controlled studies involving 161 subjects. Three exercise challenges were conducted over 12 h, and bronchoconstriction following the serial challenges was assessed as change in FEV1 compared with predose values. The mean maximal percentage decrease in FEV1 after the three exercise challenges was 5% at 0.5 h, 8% at 5.5 h, and 13% at 11.5 h postdose in the salmeterol group compared with 7, 25, and 27%, respectively, in the albuterol group and 27, 27, and 26%, respectively, in the placebo group (p < 0.001, overall treatment difference). Albuterol provided complete protection against EIB (defined as < 10% decrease in FEV1 compared with predose values) only after the first exercise challenge, but salmeterol continued to provide complete protection in the majority of subjects after each exercise challenge: 80% (44 of 55) at 0.5 h, 70% (37 of 53) at 5.5 h, and 55% (29 of 53) at 11.5 h. Electrocardiographic monitoring revealed no clinically significant changes in any treatment group 15 and 30 min following each exercise challenge. In summary, these data demonstrate that salmeterol is effective against EIB and that a single 42 micrograms dose can prevent EIB for up to 12 h.


This article has been cited by other articles:


Home page
 ChestHome page
A. Coreno, M. Skowronski, E. West, A. El-Ekiaby, and E.R. McFadden Jr
Bronchoprotective Effects of Single Doses of Salmeterol Combined With Montelukast in Thermally Induced Bronchospasm
Chest, May 1, 2005; 127(5): 1572 - 1578.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Steinshamn, M. Sandsund, M. Sue-Chu, and L. Bjermer
Effects of Montelukast and Salmeterol on Physical Performance and Exercise Economy in Adult Asthmatics With Exercise-Induced Bronchoconstriction
Chest, October 1, 2004; 126(4): 1154 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
M. J. Cawley
Exercise-Induced Asthma
Journal of Pharmacy Practice, February 1, 2003; 16(1): 59 - 67.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
K. Richter, S. Janicki, R.A. Jorres, and H. Magnussen
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline
Eur. Respir. J., May 1, 2002; 19(5): 865 - 871.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS and R. A. PAUWELS
Long-acting Inhaled beta 2-Agonist Therapy in Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. M. Edelman, J. A. Turpin, E. A. Bronsky, J. Grossman, J. P. Kemp, A. F. Ghannam, P. T. DeLucca, G. J. Gormley, D. S. Pearlman, and for the Exercise Study Group*
Oral Montelukast Compared with Inhaled Salmeterol To Prevent Exercise-Induced Bronchoconstriction: A Randomized, Double-Blind Trial
Ann Intern Med, January 18, 2000; 132(2): 97 - 104.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
{beta}2-Agonists
Can. Med. Assoc. J., November 1, 1999; 161(90111): s28 - 31.
[Full Text]

Home page
 PediatricsHome page
H. Milgrom and L. M. Taussig
Keeping Children With Exercise-induced Asthma Active
Pediatrics, September 1, 1999; 104 (3): e38 - e38.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Nelson, L. Strauss, M. Skowronski, R. Ciufo, R. Novak, and E.R. McFadden
Effect of Long-Term Salmeterol Treatment on Exercise-Induced Asthma
N. Engl. J. Med., July 16, 1998; 339(3): 141 - 146.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. E. R. Simons, T. V. Gerstner, and M. S. Cheang
Tolerance to the Bronchoprotective Effect of Salmeterol in Adolescents With Exercise-induced Asthma Using Concurrent Inhaled Glucocorticoid Treatment
Pediatrics, May 1, 1997; 99(5): 655 - 659.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
P. A. Eggleston
Are beta -Adrenergic Bronchodilators Safe?
Pediatrics, May 1, 1997; 99(5): 729 - 729.
[Full Text]

Home page
 NEJMHome page
H. S. Nelson
{beta}-Adrenergic Bronchodilators
N. Engl. J. Med., August 24, 1995; 333(8): 499 - 507.
[Full Text] [PDF]

Home page
 JWatch GeneralHome page
INHALERS PREVENT EXERCISE-INDUCED BRONCHOSPASM
Journal Watch (General), January 3, 1995; 1995(103): 3 - 3.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1994 American Thoracic Society